This expanded access program provides investigational levacetylleucine to patients with Ataxia-Telangiectasia who are not eligible for clinical trials and have no satisfactory alternative therapies.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2026-01-23.
Status change: Temporarily Not Available → Available2026-02-20